Brief: Cumberland Pharmaceuticals Announces Phase 2 Fight Dmd Trial Results For Duchenne Muscular Dystrophy Heart Disease
04/02/2025 12:42
Feb 4 (Reuters) - Cumberland Pharmaceuticals Inc
CPIX.O :
* CUMBERLAND PHARMACEUTICALS ANNOUNCES BREAKTHROUGH RESULTS
FROM
THE PHASE 2 FIGHT DMD TRIAL IN DUCHENNE MUSCULAR DYSTROPHY HEART
DISEASE
* CUMBERLAND PHARMACEUTICALS INC - IFETROBAN WELL-TOLERATED
WITH
NO SERIOUS DRUG-RELATED EVENTS
Source text: ID:nPn9B7wCBa
Further company coverage: CPIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cumberland Pharmaceuticals
See all newsBrief: Cumberland Pharmaceuticals Announces Assist-Ssc Trial Top-Line Results
Cumberland Pharmaceuticals Q2 loss widens after Apotex transaction
Brief: Cumberland Pharmaceuticals Announces Special Dividend Of $1.50 Per Share
Cumberland Pharmaceuticals Q1 revenue up 5%; to sell FDA‑approved brands to Apotex for $100 mln
NASDAQ RESUMED AT 09:38 AM